Search for Clinical Trial Results
Mantle Cell Lymphoma - 35 Studies Found
Status | Study |
Completed |
Study Name: Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Recurrent Date: 2011-03-24 Interventions: Drug: Combination of Bortezomib, Fludarabine and Cyclophosphamide bortezomib 1.3mg/m^2 i.v. on days 1, 4 |
Withdrawn |
Study Name: A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2016-04-08 Interventions:
|
Completed |
Study Name: Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2001-08-16 Interventions:
|
Active, not recruiting |
Study Name: A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2013-01-24 Interventions:
|
Recruiting |
Study Name: Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2015-02-02 Interventions:
|
NOT_YET_RECRUITING |
Study Name: Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Condition: Date: 2024-05-19 Interventions: Undergo biopsy |
RECRUITING |
Study Name: Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2024-05-19 Interventions: Given PO |
RECRUITING |
Study Name: Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma Condition: Blastoid Variant Mantle Cell Lymphoma Date: 2024-05-19 Interventions: Undergo tumor biopsy |
NOT_YET_RECRUITING |
Study Name: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na�ve Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma (MCL) Date: 2024-05-19 Interventions: Investigational Product |
RECRUITING |
Study Name: A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2024-05-19 Interventions: Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles.Each cycle is 28 days in length. |